Entity family

Browse diseases

Named diseases, disorders, syndromes, injuries, and health conditions. Examples include epilepsy, diabetes, stroke.

23,712articles mentioning diseases

125,551disease mentions

18,081distinct diseases extracted

0%of mentions human-reviewed

Filter articles

JournalContent resourceEvidence policyAutomated confidence floorArticles per pageReset filters

“Reviewed + threshold” includes every confirmed correction plus unreviewed proposals at or above the selected model score.

All extracted diseases

Showing 12,361–12,420 of 18,081, ordered by supporting articles. Choose a disease to see its evidence.

arteriovenous brachiocephalic fistula1 arteriovenous fistula or malformation1 arteriovenous shunting disorders1 arthropathic psoriasis1 artificial stone (AS) silicosis1 asbestos-related occupational diseases1 asbestos-related respiratory disease1 ascaris1 ascending aortic aneurysm1 ascending aortic pseudoaneurysm1 aseptic inflammation1 aspergillosis1 asthma attacks1 asthma-skin conditions1 asthma/wheeze1 asthma21 asthmaBreathlessness1 asthmaIntroduction1 asthmaMethods1 asthmaModel1 asthmaOdds1 asthmaPatient1 asthmaWe1 asthmagens1 asthmapregnancytoolkit1 astrocyte tumors1 asymptomatic carotid stenosis1 asymptomatic high-grade carotid stenosis1 ataxia and optic atrophy syndrome1 ataxia-telangiectasia1 ataxia-telangiectasia (AT)1 ataxic disorders1 atherosclerosis heart disease1 atherosclerosis-like1 atherosclerosis-related1 atherosclerotic CV disease1 atherosclerotic CVD1 atherosclerotic MI1 atherosclerotic cardiovascular disease (ACVD)1 atherosclerotic coronary artery disease1 atherosclerotic plaque instability1 atherosclerotic plaque vulnerability1 atherosclerotic plaquesTo1 atherothrombotic disease1 atherothrombotic stroke-related large vessel occlusion (AT-LVO)1 atopic dermatitis-like symptoms1 atraumatic or iatrogenic fractures1 atraumatic subdural hematoma (SDH)1 atrial arrhythmogenesis1 atrial bigeminy1 atrial fibrillation flutter1 atrial fibrillation or flutter1 atrial fibrillation-related stroke1 atrial fibrillationMethods1 atrial ganglionated plexi1 atrial or ventricular septal defects1 atrial secondary MR1 atrioventricular nodal reentrant tachycardia1 atrophic endometrium1 attention deficit and hyperactivity disorder1

View all 18,081 diseases on one page

Articles mentioning diseases

23,712 articles · page 260 of 1976

PO:09:234 Neuropsychiatric involvement in patients with systemic lupus erythematosus

lupusscimed · abstract · 2026-03-01 · 9 matching annotations

93.5%

NPSLE SLE Neuropsychiatric SLE epilepsy

…(CNS) and peripheral nervous system (PNS)—based on the 1999 ACR NPSLE case definitions and current literature. Statistical analyses w…

PO:10:257 Addition of a calcineurin inhibitor (CNI) to glucocorticoids (GC) and mycophenolate mofetil (MMF) increased the frequency of renal response in lupus nephritis (LN) due to a reduction in proteinuria

lupusscimed · abstract · 2026-03-01 · 9 matching annotations

97.5%

lupus nephritis SLE systemic lupus erythematosus Anifrolumab hydroxychloroquine tacrolimus

…vel at 12 hours of 4-6 ug/L.Results Before TAC, the duration of lupus nephritis (LN) was 46 (in the range of 12-162) months. The drug therapy p…

PO:10:271 From patient voice to clinical practice: recommendations from the national evaluation of the lupus service in NHS wales

lupusscimed · abstract · 2026-03-01 · 9 matching annotations

99.8%

lupus Rheumatology biologic treatments Welsh Government CEDAR NHS British Society for Rheumatology

…ental health support, inter-speciality fragmented care, and low lupus awareness among non-specialists. The findings provided a clear …

PO:11:274 RESET SLE: clinical trial evaluating rese-cel (resecabtagene autoleucel), a fully human, autologous 4–1BB anti-CD19 CAR T cell therapy in non-renal SLE and lupus nephritis (LN)

lupusscimed · abstract · 2026-03-01 · 9 matching annotations

99.7%

SLE Rese-cel NCT06121297

… allowing patients to achieve meaningful clinical responses off SLE therapies. Both cohorts are fully enrolled, with additional pos…

PT1:08 A cross-reactive response to symmetrical dimethylarginine defines anti-Sm autoantibodies in systemic lupus erythematosus

lupusscimed · abstract · 2026-03-01 · 9 matching annotations

96.8%

Systemic lupus erythematosus SLE SLE-specific

…Objectives Systemic lupus erythematosus (SLE) is a chronic autoimmune disease causing multi-organ damag…

PT2:02 Plasma metabolomic profiling reveals serine-centered immunometabolic modulation by SGLT2 inhibition in lupus nephritis

lupusscimed · abstract · 2026-03-01 · 9 matching annotations

98.1%

lupus nephritis SLE systemic lupus erythematosus dapagliflozin dapagliflozin-associated Dapagliflozin-treated

…y provides novel insights into systemic metabolic remodeling in lupus nephritis and identifies dapagliflozin-associated shifts in amino acid an…

PT3:03 Rapid Oral glucocorticoid discontinuation or dose reduction among US patients with SLE receiving belimumab in a real-world setting

lupusscimed · abstract · 2026-03-01 · 9 matching annotations

95.9%

SLE lupus LN Belimumab prednisone-equivalent BEL GSK OGC

…roportion of moderate (74.3% vs 66.9%) or severe (3.7% vs 2.2%) SLE, but similar baseline organ damage ( table 1). Baseline moderat…

PT3:04 Correlation between clinical remission and steroid withdrawal in systemic lupus erythematosus: a retrospective analysis of a monocentric cohort characterized by intensive immunosuppressant use

lupusscimed · abstract · 2026-03-01 · 9 matching annotations

99.3%

SLE diabetes mellitus osteoporosis with fracture cataract arterial hypertension cardiovascular events Rituximab hydroxychloroquine Belimumab Anifrolumab

…ing that steroid-free remission is a realistic clinical goal in SLE management. Steroid-free management of more inflammatory manife…

PT4:05 Tofacitinib versus belimumab in maintenance therapy of systemic lupus erythematosus: a real-world CSTAR cohort study

lupusscimed · abstract · 2026-03-01 · 9 matching annotations

95.4%

SLE Systemic lupus erythematosus Lupus Erythematosus Belimumab Tofacitinib TOF BEL

…d, multicenter, retrospective cohort study based on the Chinese SLE Treatment and Research Registry (CSTAR). Maintenance therapy wa…

PT6:03 Autoantibody signatures predict atherosclerosis progression and statin response in juvenile-onset systemic lupus erythematosus

lupusscimed · abstract · 2026-03-01 · 9 matching annotations

87.6%

JSLE JSLE-specific Cardiovascular disease CVD-risk atorvastatin atorvastatin-arm statin

…ersus placebo (1:1) across 21 North American sites. Ninety-four JSLE patients (mean [SD] age 15.3 [2.4] years; 78% female) with matc…

PT7:06 Bridging physician-defined targets and patient-perceived health: associations with PASS in the large multicenter systemic lupus erythematosus cohort RELESSER

lupusscimed · abstract · 2026-03-01 · 9 matching annotations

94.8%

systemic lupus erythematosus SLE fibromyalgia SLEDAI-2K DORIS-R

…o identify clinical and socio-demographic correlates of PASS in systemic lupus erythematosus (SLE).Methods We analyzed data from the large multicenter RELES…

S15:02 Dapirolizumab pegol and flare reduction in patients with SLE in a 48-week phase 3 trial: an updated post hoc analysis of alternative definitions of flares that reflect clinical practice

lupusscimed · abstract · 2026-03-01 · 9 matching annotations

88.0%

BILAG-2004 dapirolizumab pegol DZP

… of patients receiving PBO+SOC had moderate and moderate/severe BILAG-2004 flares using the alternative definitions; lower proportions of …